[1]
|
李金金, 轩伟霞, 张晓菊. 恶性胸腔积液产生的机制研究进展[J]. 国际呼吸杂志, 2018, 38(10): 783-786.
|
[2]
|
Jany, B. and Welte, T. (2019) Pleural Effusion in Adults-Etiology, Diagnosis, and Treatment. Deutsches Arzteblatt International, 116, 377-386. https://doi.org/10.3238/arztebl.2019.0377
|
[3]
|
Koegelenberg, C.F.N., Shaw, J.A., Irusen, E.M. and Gary Lee, Y.C. (2018) Contemporary Best Practice in the Management of Malignant Pleural Effu-sion. Therapeutic Advances in Respiratory Disease, 12.
https://doi.org/10.1177/1753466618785098
|
[4]
|
李克爱, 郝仲芳, 陈洪萍, 苗培田, 雒建雷. 腔内注射贝伐珠单抗联合奥沙利铂治疗肺癌恶性胸腔积液的效果[J]. 广东医学, 2019, 40(23): 3327-3330. https://doi.org/10.13820/j.cnki.gdyx.20191241
|
[5]
|
Folkman, J. (1971) Tumor Angiogenesis: Therapeutic Impli-cations. The New England Journal of Medicine, 285, Article ID: 11826. https://doi.org/10.1056/NEJM197111182852108
|
[6]
|
Bradshaw, M., Mansfield, A. and Peikert, T. (2013) The Role of Vascular Endothelial Growth Factor in the Pathogenesis, Diagnosis and Treatment of Malignant Pleural Effusion. Current Oncology Reports, 15, 207-216.
https://doi.org/10.1007/s11912-013-0315-7
|
[7]
|
Fafliora, E., Hatzoglou, C., Gourgoulianis, K.I., et al. (2016) Sys-tematic Review and Meta-Analysis of Vascular Endothelial Growth Factor as a Biomarker for Malignant Pleural Effu-sions. Physiological Reports, 4, e12978.
https://doi.org/10.14814/phy2.12978
|
[8]
|
Zachary, I. (2001) Signaling Mechanisms Mediating Vascular Protective Actions of Vascular Endothelial Growth Factor. American Journal of Physiology-Cell Physiology, 280, C1375-C1386.
https://doi.org/10.1152/ajpcell.2001.280.6.C1375
|
[9]
|
Bradshaw, M., Mansfield, A. and Peikert, T. (2013) The Role of Vascular Endothelial Growth Factor in the Pathogenesis, Diagnosis and Treatment of Malignant Pleural Effusion. Current Oncology Reports, 15, 207-216.
https://doi.org/10.1007/s11912-013-0315-7
|
[10]
|
Fujimoto, K., Hosotani, R., Wada, M., et al. (1998) Expression of Two Angiogenic Factors, Vascular Endothelial Growth Factor and Platelet-Derived Endothelial Cell Growth Factor in Human Pancreatic Cancer, and Its Relationship to Angiogenesis. European Journal of Cancer, 34, 1439-1447. https://doi.org/10.1016/S0959-8049(98)00069-0
|
[11]
|
Ikeda, N., Adachi, M., Taki, T., et al. (1999) Prognostic Sig-nificance of Angiogenesis in Human Pancreatic Cancer. British Journal of Cancer, 79, 1553-1563. https://doi.org/10.1038/sj.bjc.6690248
|
[12]
|
Maeda, K., Chung, Y.S., Ogawa, Y., et al. (1996) Prognostic Value of Vascular Endothelial Growth Factor Expression in Gastric Carcinoma. Cancer, 77, 858-863.
https://doi.org/10.1002/(SICI)1097-0142(19960301)77:5<858::AID-CNCR8>3.0.CO;2-A
|
[13]
|
Takahashi, Y., Cleary, K.R., Mai, M., et al. (1996) Significance of Vessel Count and Vascular Endothelial Growth Factor and Its Re-ceptor (KDR) in Intestinal-Type Gastric Cancer. Clinical Cancer Research, 2, 1679-1684.
|
[14]
|
Lee, J.C., Chow, N.H., Wang, S.T. and Huang, S.M. (2000) Prognostic Value of Vascular Endothelial Growth Factor Expression in Colorectal Cancer Patients. European Journal of Cancer, 36, 7453.
https://doi.org/10.1016/S0959-8049(00)00003-4
|
[15]
|
Takahashi, Y., Kitadai, Y., Bucana, C.D., et al. (1995) Ex-pression of Vascular Endothelial Growth Factor and Its Receptor, KDR, Correlates with Vascularity, Metastasis, and Proliferation of Human Colon Cancer. Cancer Research, 55, 3964-3968.
|
[16]
|
Hamed, E.A., El-Noweihi, A.M., Mo-hamed, A.Z. and Mahmoud, A. (2004) Vasoactive Mediators (VEGF and TNF- Alpha) in Patients with Malignant and Tuberculous Pleural Effusions. Respirology, 9, 816.
https://doi.org/10.1111/j.1440-1843.2003.00529.x
|
[17]
|
Gerber, H.P. and Ferrara, N. (2005) Pharmacology and Pharmacodynamics of Bevacizumab as Monotherapy or in Combination with Cytotoxic Therapy in Preclinical Studies. Cancer Research, 65, 671-680.
https://doi.org/10.1158/0008-5472.671.65.3
|
[18]
|
Numnum, T.M., Rocconi, R.P., Whitworth, J. and Barnes, M.N. (2006) The Use of Bevacizumab to Palliate Symptomatic Ascites in Patients with Refractory Ovarian Carcinoma. Gyne-cologic Oncology, 102, 4258.
https://doi.org/10.1016/j.ygyno.2006.05.018
|
[19]
|
Ferrara, N. and Henzel, W.J. (1989) Pituitary Follicular Cells Se-crete a Novel Heparin-Binding Growth Factor Specific for Vascular Endothelial Cells. Biochemical and Biophysical Re-search Communications, 161, 851-858.
https://doi.org/10.1016/0006-291X(89)92678-8
|
[20]
|
Ferrara, N., Gerber, H.P. and LeCouter, J. (2003) The Biolo-gy of VEGF and Its Receptors. Nature Medicine, 9, 669- 676. https://doi.org/10.1038/nm0603-669
|
[21]
|
Hicklin, D.J. and Ellis, L.M. (2005) Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogene-sis. Journal of Clinical Oncology, 23, 1011-1027. https://doi.org/10.1200/JCO.2005.06.081
|
[22]
|
Ku, D.D., Zaleski, J.K., Liu, S. and Brock, T.A. (1993) Vascular Endothelial Growth Factor Induces EDRF-Dependent Relaxation in Coro-nary Arteries. American Journal of Physiology, 265, H586-H592.
https://doi.org/10.1152/ajpheart.1993.265.2.H586
|
[23]
|
Brown, L.F., Detmar, M., Claffey, K., et al. (1997) Vascu-lar Permeability Factor/Vascular Endothelial Growth Factor: A Multifunctional Angiogenic Cytokine. EXS, 79, 233-269. https://doi.org/10.1007/978-3-0348-9006-9_10
|
[24]
|
Mohammed, K.A., Nasreen, N., Hardwick, J., et al. (2001) Bacterial Induction of Pleural Mesothelial Monolayer Barrier Dysfunction. The American Journal of Physiology-Lung Cellular and Molecular Physiology, 281, L119-L125.
https://doi.org/10.1152/ajplung.2001.281.1.L119
|
[25]
|
Ishii, H., Yazawa, T., Sato, H., et al. (2004) Enhancement of Pleural Dissemination and Lymph Node Metastasis of Intrathoracic Lung Cancer Cells by Vascular Endothelial Growth Factors (VEGFs). Lung Cancer, 45, 32537.
https://doi.org/10.1016/j.lungcan.2004.02.021
|
[26]
|
Yano, S., Shinohara, H., Herbst, R.S., Kuniyasu, H., Bucana, C.D., Ellis, L.M., et al. (2000) Production of Experimental Malignant Pleural Effusions Is Dependent on Invasion of the Pleura and Expression of Vascular Endothelial Growth Factor/Vascular Permeability Factor by Human Lung Cancer Cells. The American Journal of Pathology, 157, 1893- 1903. https://doi.org/10.1016/S0002-9440(10)64828-6
|
[27]
|
Chellappan, D.K., Leng, K.H., Jia, L.J., et al. (2018) The Role of Bevacizumab on Tumour Angiogenesis and in the Management of Gynaecological Cancers: A Review. Biomedi-cine & Pharmacotherapy, 102, 1127-1144.
https://doi.org/10.1016/j.biopha.2018.03.061
|
[28]
|
Sandler, A. (2007) Bevacizumab in Non Small Cell Lung Cancer. Clinical Cancer Research, 13, s4613-s4617.
https://doi.org/10.1158/1078-0432.CCR-07-0647
|
[29]
|
Nie, K.K., Zhang, Z., You, Y.H., et al. (2020) A Random-ized Clinical Study to Compare Intrapleural Infusion with Intravenous Infusion of Bevacizumab in the Management of Malignant Pleural Effusion in Patients with Non-Small-Cell Lung Cancer. Thoracic Cancer, 11, 8-14. https://doi.org/10.1111/1759-7714.13238
|
[30]
|
Bradshaw, M., Mansfifield, A. and Peikert, T. (2013) The Role of Vascular Endothelial Growth Factor in the Pathogenesis, Diagnosis and Treatment of Malignant Pleural Effusion. Cur-rent Oncology Reports, 15, 207-216.
https://doi.org/10.1007/s11912-013-0315-7
|
[31]
|
Song, X., Chen, D., Guo, J., et al. (2018) Better Efficacy of Intra-pleural Infusion of Bevacizumab with Pemetrexed for Malignant Pleural Effusion Mediated from Nonsquamous Non-Small Cell Lung Cancer. OncoTargets and Therapy, 11, 8421-8426. https://doi.org/10.2147/OTT.S184030
|
[32]
|
Kitamura, K., Kubota, K. ando, M., et al. (2013) Bevacizumab plus Chemotherapy for Advanced Non-Squamous Non-Small-Cell Lung Cancer with Malignant Pleural Effusion. Cancer Chemotherapy and Pharmacology, 71, 457-461.
https://doi.org/10.1007/s00280-012-2026-4
|
[33]
|
Qi, N., Li, F., Li, X., et al. (2016) Combination Use of Paclitaxel and Avastin Enhances Treatment Effect for the NSCLC Patients with Malignant Pleural Effusion. Medicine (Baltimore), 95, e5392.
https://doi.org/10.1097/MD.0000000000005392
|
[34]
|
Wu, D., Cong, Y., Zhang, Z.R., et al. (2022) A Phase II Study of Bevacizumab in Non-Squamous, Non-Small-Cell Lung Cancer Patients with Malignant Pleural Effusion. Future Oncology (London, England), 18, 669-677.
https://doi.org/10.2217/fon-2021-1035
|
[35]
|
O’Reilly, M.S., Boehm, T., Shing, Y., et al. (1997) Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth. Cell, 88, 277-285. https://doi.org/10.1016/S0092-8674(00)81848-6
|
[36]
|
Nasreen, N., Mohammed, K.A., Sanders, K., et al. (2003) Pleural Mesothelial Cell (PMC) Defense Mechanisms against Malignancy. Oncology Research, 14, 155-161. https://doi.org/10.3727/000000003771013053
|
[37]
|
Tian, P.W., Shen, Y.C., Feng, M., et al. (2015) Diagnostic Accuracy of Endostatin for Malignant Pleural Effusion: A Clinical Study and Meta-Analysis. Postgraduate Medicine, 127, 529-534.
https://doi.org/10.1080/00325481.2015.1048180
|
[38]
|
Wang, J.W., Sun, Y., Liu, Y.Y., et al. (2005) Results of Randomized, Multicenter, Double-Blind Phase III Trial of Rh-Endostatin (YH-16) in Treatment of Advanced Non-Small Cell Lung Cancer Patients. Chinese Journal of Lung Cancer, 8, 283-290.
|
[39]
|
Wang, X.J., Miao, K., Luo, Y., et al. (2018) Randomized Controlled Trial of Endostar Combined with Cisplatin/Pemetrexed Chemotherapy for Elderly Patients with Advanced Malignant Pleural Effusion of Lung Adenocarcinoma. Journal of B.U.O.N.: Official Journal of the Bal-kan Union of Oncology, 23, 92-97
|
[40]
|
Zhao, W.-Y. Chen, D.-Y., Chen, J.-H. and Ji, Z.-N. (2014) Effects of Intracavi-tary Administration of Endostar Combined with Cisplatin in Malignant Pleural Effusion and Ascites. Cell Biochemistry and Biophysics, 70, 623-628.
https://doi.org/10.1007/s12013-014-9965-9
|
[41]
|
Qin, S., Yang, L., Liang, J., et al. (2017) Prospective, Random-ized, Multicenter Clinical Study of Endometrial and Cisplatin in the Treatment of Malignant Pleural Effusion. Chinese Journal of Clinical Oncology, 22, 193-202. (In Chinese)
|
[42]
|
Hu, X., Shi, Y., Wang, H., et al. (2015) A Clinical Study on Intra-Thoracic Chemotherapy of Recombinant Human Endostatin Combined with Cisplatin for Malignant Pleural Ef-fusion. Clinical Medicine Journal, 3, 23-27.
|
[43]
|
Wei, H.M., Qin, S.K., Yin, X.J., et al. (2015) Endostar Inhibits Asci-tes Formation and Prolongs Survival in Mouse Models of Malignant Ascites. Oncology Letters, 9, 2694-2700. https://doi.org/10.3892/ol.2015.3134
|
[44]
|
Ma, X.Q., Yao, Y.W., Yuan, D.M., Liu, H.B., et al. (2012) Recombi-nant Human Endostatin Endostar Suppresses Angiogenesis and Lymphangiogenesis of Malignant Pleural Effusion in Mice. PLOS ONE, 7, e53449.
https://doi.org/10.1371/journal.pone.0053449
|
[45]
|
Tong, R.T., et al. (2004) Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient across the Vasculature and Improves Drug Penetration in Tumors. Cancer Research, 64, 3731- 3736. https://doi.org/10.1158/0008-5472.CAN-04-0074
|
[46]
|
Rong, B.X., Cai, X.G., Liu, H., Gao, W.L. and Yang, S.Y. (2016) Thoracic Perfusion of Recombinant Human Endostatin (Endostar) Combined with Chemotherapeutic Agents ver-sus Chemotherapeutic Agents Alone for Treating Malignant Pleural Effusions: A Systematic Evaluation and Me-ta-Analysis. BMC Cancer, 16, 888.
https://doi.org/10.1186/s12885-016-2935-4
|
[47]
|
林卫佳, 张亚平, 李峰, 项保利, 张秀珑, 张志华, 袁胜芳. 重组人血管内皮抑素对恶性胸腔积液的治疗效果[J]. 临床肺科杂志, 2022, 27(9): 1407-1410.
|
[48]
|
杨璞, 李反念, 豆瑞刚, 曹万乐, 刘扬, 朱梓铭, 高计林, 刘军校, 刘世伟. 不同剂量恩度胸腔灌注治疗肺癌恶性胸腔积液的效果及安全性观察[J]. 药学与临床研究, 2022, 30(4): 339-342.
https://doi.org/10.13664/j.cnki.pcr.2022.04.011
|